Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353878 | 0.88 | HSD17B10 (0.56) | HSD17B10ELANEPRTN3LMNASMN1; SMN2 | |
| SCHEMBL9112418 | 0.83 | LMNA (0.55) | HSD17B10KYNULMNASMN1; SMN2 | |
| SCHEMBL5370600 | 0.80 | LMNA (0.55) | HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL7378563 | 0.80 | SYK (0.57) | HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL5073968 | 0.80 | HSD17B10 (0.44) | HSD17B10 | |
| SCHEMBL20681083 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2 | |
| SCHEMBL28522803 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2 | |
| SCHEMBL1287197 | 0.79 | HTT (0.55) | LMNASMN1; SMN2 | |
| SCHEMBL28522801 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2 | |
| SCHEMBL9293928 | 0.78 | LMNA (0.59) | HSD17B10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423012-B2 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | HSD17B10 1339/4885KYNU 429/4885ELANE 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.